Kari Klungsøyr, MD, PhD
Original Research
Atomoxetine and Prevalence of Major Congenital Malformations
January 16, 2023
Little is known about the safety of atomoxetine, a non-stimulant treatment for attention-deficit/hyperactivity disorder. This study assessed the prevalence of major congenital malformations after first-trimester exposure to atomoxetine.
